Publications

Included here is a list of publications from OCG programs. All published data are available to the research community through the program-specific data matrices.

* denotes publications from the CTD2 initiative that are results of intra-Network collaborations

 

CTD²
March 01, 2018
ASSAY and Drug Development Technologies

CTD2 scientists at Emory University developed a high-throughput time-resolved fluorescence resonance energy transfer assay to discover small-molecule inhibitors of receptor binding protein, NSD3 protein-protein interactions.

CTD²
February 16, 2018
ACS Chemical Biology

Review of methods with a focus on chemical-genetic screens used in the identification of the mechanisms of action of small molecules.

CTD²
February 13, 2018
Cell Reports

CTD2 scientists at UCSF (1) identified two major subtypes of KRAS mutant cancers of the lung, pancreas, and the large intestine which differentially engage effector pathways. These findings can be used to develop effective combination of therapies.

CTD²
February 05, 2018
Cancer Res

Studies demonstrated that epithelial-to-mesenchymal transition-inducing transcription factor, Snail, represses tumor suppressive RNA splicing regulatory protein, ESRP1, and promotes tumorigenesis in lung cancer.

CTD²
February 05, 2018
Molecular Cancer Research

Researchers at UCSF (2) discovered that antisecretory factor decreases osmotic adaptation, increases drug uptake, and promotes anti-tumor activity in glioblastoma.

CTD²
February 01, 2018
Nature Biotechnology

CTD2 investigators developed an orthogonal CRISPR screening method that can quantify loss- and gain-of-function phenotypes in the same cell. This method is useful to determine gene dependencies and direction of genetic interactions.

CTD²
January 23, 2018
The Journal of Clinical Investigation

CTD2 researchers engineered T cell receptor with oncogenic mutation BRAFV600E- specific CD4+ T cells in a patient with acral melanoma. These engineered T cells may have antitumor effects and enhance CD8+ T cell responses in patients with BRAF mutated cancers.

Pages

CSVXML